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Abstract: Ecthyma	gangrenosum	is	a	rare	skin	infection	classically	associated	with	Pseudomonas	aeruginosa.	We	performed	
a retrospective study of all cases diagnosed with ecthyma gangrenosum from 2004-2010 in a university hospital in Mexico (8 
cases,	5	female	patients	and	3	male	patients,	ages	between	4	months	and	2	years).	The	most	common	risk	factor	for	ecthyma	
gangrenosum	is	neutropenia	in	immunocompromised	patients.	In	previously	healthy	patients,	immunological	evaluation	is	
important	to	rule	out	underlying	immunodeficiency.	Ecthyma	gangrenosum	in	healthy	patients	has	a	high	mortality	rate	and	
early diagnosis and aggressive antibiotic treatment is imperative as it can improve patients’ prognosis.
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INTRODUCTION
Ecthyma	gangrenosum	(EG)	 is	a	rare	skin	 infection	classi-
cally associated with Pseudomona aeruginosa. It can be a potentially 
fatal systemic infection and can be a manifestation of an underlying 
clinical entity.1-3
We performed a retrospective study of all EG cases from 
2004	to	2010	in	a	university	hospital	in	Monterrey,	Mexico.
CASE REPORT
We report 8 cases that occurred with 5 female patients and 
3	male	patients,	ages	between	4	months	and	2	years.	Four	patients	
were	apparently	previously	healthy	at	admission,	and	the	other	4	
had a degree of immunosuppression (hemophagocytic lymphohis-
tiocytosis,	undifferentiated	embryonic	liver	sarcoma	and	desnutri-
tion	(Table	1)).	All	patients	presented	at	our	institution	in	a	febrile	
state. They also had a history of erythema that progressed to pus-
tules	and	ulcerations	surrounded	by	erythema,	some	of	them	cov-
ered	by	a	necrotic	crust.	Two	patients	had	the	lesions	on	the	face,	3	
on	the	extremities,	1	in	the	supraclavicular	region,	1	in	the	gluteal	
region,	and	1	on	the	face	and	extremities	(Figures	1	and	2).	Work-
up	was	significant	 for	neutrophilia	 in	3	patients,	neutropenia	 in	4	
patients,	 thrombocytopenia	 in	7	patients,	and	thrombocytosis	 in	1	
patient. Bacteria blood cultures from 7 patients grew Pseudomona 
aeruginosa. The patient with negative blood culture showed a posi-
tive result in the bacterial wound culture for Pseudomona aeruginosa. 
On	immunological	 investigation,	2	of	the	apparently	healthy	chil-
dren	were	diagnosed	with	granulomatous	chronic	disease,	with	di-
hydrorhodamine	123	(DHR).	Seven	patients	received	combination	
therapy	 (4	 ceftazidime	 and	 amikacin,	 2	 imipenem	 and	 amikacin,	
1	meropenem	and	amikacin,	and	1	meropenem	and	ciprofloxacin)	
and 1 received monotherapy with imipenem. Five patients had fa-
vorable	evolution,	with	resolution	of	the	skin	lesions	and	with	close	
follow-up.	Three	patients	(including	the	2	previously	healthy)	died	
secondary to sepsis.
DISCUSSION
The	most	common	risk	factor	for	EG	is	neutropenia	in	im-
munocompromised	patients.	Although	it	rarely	occurs	in	previous-
ly	healthy	patients,	50%	of	these	patients	reveal	a	primary	subclin-
ical	immunodeficiency	or	underwent	recent	antibiotic	therapy.2,4 In 
previously	 healthy	 patients,	 the	 immunological	 evaluation	 is	 im-
portant	to	rule	out	underlying	immunodeficiencies.2
EG has also been described in association with other patho-
gens including Aeromonas hydrophila,	 Staphylococcus aureus,	 Strep-
tococcus pyogenes,	 Serratia marcescens,	 Klebsiella	 pneumoniae,	 Xan-
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Table 1: Study of 8 cases with ecthyma gangrenosum
Case Age/Sex Localization
Previously healthy or 
immunocompromised
Laboratory findings Hemoculture Treatment Outcome
1 9 months Face Previously healthy
Granulomatous chronic 
disease
Neutrophilia
Thrombocytopenia
+ Ceftazidime	and	
amikacin
Favorable
2 10 months 
Male
Extremities Previously healthy
Granulomatous chronic 
disease
Neutrophilia
Thrombocytosis
+ Ceftazidime	and	
amikacin
Favorable
3 13 months
Female
Face Immunocompromised
Desnutrition
Leukopenia
Thrombocytopenia
+ Imipenem Favorable
4 5 months
Female
Gluteal region Immunocompromised
Hemophagocytic 
lymphohistiocytosis
Neutropenia
Thrombocytopenia
+ Ceftazidime	and	
amikacin
Favorable
5 5 months
Female
Face and 
extremities
Immunocompromised
Desnutrition
Neutrophilia
Thrombocytopenia
+ Ceftazidime	and	
amikacin
Deceased
6 4 months
Female
Extremities Previously healthy Neutropenia
Thrombocytopenia
-
Skin	culture	+
Imipenem and 
amikacin
Deceased
7 2 years
Female
Supraclavicular 
region
Immunocompromised
Undifferentiated 
Embryonic Liver Sarcoma
Neutropenia
Thrombocytopenia
+ Meropenem and 
ciprofloxacin
Favorable
8 6 months
Male
Extremities Previously healthy Thrombocytopenia + Meropenem and 
amikacin
Deceased
FIgure 1: 
Ecthyma gangrenosum. 
(A)	Day	4	of	hospitaliza-
tion: patient presenting 
with erythema and edema 
on	the	left	cheek.	Lower	
lip showing ulceration 
with	necrotic	tissue;	
(B) day 7 showing new 
erythematous areas on the 
upper lip 
A B
thomonas maltophilia	,	Morganella	morganii,	Escherichia	coli,	Citrobacter	
freundii,	 Corynebacterium	 diphtheriae,	Neisseria	 gonorrhoeae,	 Yersinia	
pestis,	Candida	albicans,	Aspergillus fumigatus,	Mucormycosis,	Fusari-
um solani,	Scytalidium dimidiatum,	Pseudallescheria boydii,	and	Curvu-
laria species.1-3
Two types of EG have been described: the classical or bac-
teremic	form,	secondary	to	hematogenous	spread;	and	the	localized	
EG	or	nonsepticemic	form,	in	which	the	lesion	is	located	at	the	site	
of	inoculation	of	the	organism	into	the	skin.1
Antibiotic	 therapy	with	 spectrum	 for	Pseudomonas aerugi-
nosa	 includes	aminoglycosides,	third-	and	fourth-generation	ceph-
alosporins,	 β-lactam	 antibiotics,	 and	 broad-spectrum	 penicillins.	
In addition to the results of susceptibility tests for the isolate from 
the	patient,	local	patterns	of	susceptibility	for	each	hospital	should	
be considered in the initial choice of treatment. Some studies com-
paring combination therapy with monotherapy reveal that the regi-
mens do not affect mortality rates.5-7
Prognosis depends on the host and on the degree of immu-
nosuppression.4 The disease has a high mortality rate. In patients 
with EG and septicemia secondary to Pseudomonas,	 it	ranges	from	
38%-77%,	 and	 in	 patients	with	 no	 sepsis,	 it	 is	 described	 in	 about	
15%.8 The most important prognostic factor of mortality in invasive 
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forms is the presence of neutropenia at diagnosis.9 Luigi et al. re-
ported that severe sepsis by P. aeuruginosa can occur in previously 
healthy children with a mortality rate of 55%.10
Immunological evaluation is essential in all the patients 
(including	the	apparently	healthy	ones)	as	immunosuppression	can	
drastically change the prognosis. EG in healthy patients has a high 
mortality rate and early diagnosis and aggressive antibiotic treat-
ment is imperative as it can improve the patient’s prognosis. q
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FIgure 2: Progression of ecthyma gangrenosum on the left arm. (A)	Initial	presentation	with	erythematous	nodule;	(B)	increase	in	size	of	
the	area	with	erythema	and	ulceration;	(C) Ulceration with central necrotic crust 
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